Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Net Income (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Net Income for 2 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 195.92% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.1 million through Dec 2025, down 123.15% year-over-year, with the annual reading at -$838059.0 for FY2025, 93.87% up from the prior year.
  • Net Income for Q4 2025 was $1.9 million at Neuphoria Therapeutics, up from -$9.9 million in the prior quarter.
  • The five-year high for Net Income was $11.3 million in Q1 2025, with the low at -$9.9 million in Q3 2025.